CDH Investments Backs Chinese Biotech Start-Up In $23M Series A Round

Login to View

Chinese biotechnology start-up GemPharmatech has raised RMB160 million (US$23.24 million) in a series A round of financing from investors including the country’s alternative asset management firm CDH Investments, according to a company statement.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in